Tyrphostin AG30

Tyrphostin AG30 (AG30) is a potent and selective EGFR tyrosine kinase inhibitor. Tyrphostin AG30 (AG30) selectively inhibits self renewal induction by c-ErbB, and is able to inhibit activation of STAT5 by c-ErbB in primary erythroblasts[1][2].

Product Specifications

CAS Number

[122520-79-0]

Product Name Alternative

AG30

UNSPSC

12352005

Hazard Statement

H302+H312+H332, H315, H319

Target

EGFR

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/tyrphostin-ag30.html

Concentration

10mM

Purity

99.70

Solubility

DMSO : 125 mg/mL (ultrasonic)

Smiles

O=C(/C(C#N)=C/C1=CC=C(C(O)=C1)O)O

Molecular Formula

C10H7NO4

Molecular Weight

205.17

Precautions

H302+H312+H332, H315, H319

References & Citations

[1]Volberg T, et al. The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J. 1992 May;11 (5) :1733-42.|[2]Wessely O, et al. Distinct roles of the receptor tyrosine kinases c-ErbB and c-Kit in regulating the balance between erythroid cell proliferation and differentiation. Cell Growth Differ. 1997 May;8 (5) :481-93.|[3]Banerjee S, et al. Epidermal growth factor induces WISP-2/CCN5 expression in estrogen receptor-alpha-positive breast tumor cells through multiple molecular cross-talks. Mol Cancer Res. 2005 Mar;3 (3) :151-62.